$115.87
1.64%
Nasdaq, Nov 19, 04:00 pm EST. Closed.
ISIN
US45337C1027
Symbol
INCY

Incyte Stock price

$115.87
+2.62 2.31% 1M
+20.27 21.20% 6M
+17.10 17.31% YTD
+14.55 14.36% 1Y
+61.16 111.79% 3Y
+51.36 79.62% 5Y
+7.77 7.19% 10Y
+110.53 2,069.85% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-1.93 1.64%
ISIN
US45337C1027
Symbol
INCY
Industry

AI Insights on Incyte Insights AI Insights on Incyte

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$23.6b
Enterprise Value
$19.8b
Net debt
positive
Cash
$3.9b
Shares outstanding
204.0m
Valuation
P/E
58.5
P/S | estimate
3.9 | 3.8
EV/Sales | estimate
3.3 | 3.2
EV/FCF | ex SBC
28.9 | 47.0
P/B
4.2
Financial Health
Equity Ratio
74.3%
Return on Equity
24.9%
ROCE
12.0%
ROIC
14.4%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$263.3m | 4.4%
SBC as % of FCF
38.5%
SBC Growth 1Y
1.7%
Share Count Growth 1Y
4.0%
Shareholder Yield
-4.0%
Financials
Revenue | estimate
$6.0b | $6.2b
EBITDA
$728.6m
EBIT
$701.0m
Net Income
$403.4m
Free Cash Flow | ex SBC
$684.9m | $421.5m
Growth
Revenue | estimate
24.9% | 20.1%
EBITDA
-43.1%
EBIT
-44.2%
Net Income
-66.1%
Free Cash Flow
-42.8%
Margin
Gross
93.2%
EBITDA
12.1%
EBIT
11.7%
Net
6.7%
Free Cash Flow | ex SBC
11.4% | 7.0%
More
EPS
$2.0
FCF per Share
$3.4
Short interest
8.9%
Employees
3k
Rev per Employee
$1.8m

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Incyte forecast:

19x Buy
54%
16x Hold
46%

Analyst Opinions

35 Analysts have issued a Incyte forecast:

Buy
54%
Hold
46%

Incyte Events

Past Events
NOV
17
UBS Global Biopharma Conference 2026
3 days ago
NOV
17
Jefferies London Healthcare Conference
3 days ago
NOV
10
8th Annual Wolfe Research Healthcare Conference
10 days ago
OCT
29
Q3 2026 Earnings Call
22 days ago
OCT
26
Special Call - Incyte Corporation
25 days ago
SEP
16
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
SEP
10
12th Annual Cantor Fitzgerald Global Healthcare Conference
2 months ago
SEP
9
Wells Fargo 21st Annual Healthcare Conference
2 months ago
JUL
28
Q2 2026 Earnings Call
4 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
JUN
8
Incyte Corporation, Vega Therapeutics, Inc. - M&A Call
5 months ago
MAY
19
RBC Capital Markets Global Healthcare Conference 2026
6 months ago
MAY
13
Bank of America Global Healthcare Conference 2026
6 months ago
APR
28
Q1 2026 Earnings Call
7 months ago
MAR
11
Barclays 28th Annual Global Healthcare Conference
8 months ago
MAR
10
Leerink Global Healthcare Conference 2026
8 months ago
MAR
2
TD Cowen 46th Annual Health Care Conference
9 months ago
FEB
10
Q4 2025 Earnings Call
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
7
Special Call - Incyte Corporation
12 months ago
DEC
3
Evercore 8th Annual Healthcare Conference
12 months ago
DEC
2
Citi Annual Global Healthcare Conference 2025
12 months ago
NOV
18
Jefferies London Healthcare Conference 2025
about one year ago
NOV
10
Guggenheim Securities 2nd Annual Healthcare Innovation Conference
about one year ago
OCT
28
Q3 2025 Earnings Call
about one year ago

Financial data from Incyte

Sep '26
+/-
%
6,011 6,011
25% 25%
100%
- Direct Costs 412 412
31% 31%
7%
5,599 5,599
24% 24%
93%
- Selling and Administrative Expenses 1,435 1,435
9% 9%
24%
- Research and Development Expense 3,436 3,436
80% 80%
57%
729 729
43% 43%
12%
- Depreciation and Amortization 28 28
10% 10%
0%
EBIT (Operating Income) EBIT 701 701
44% 44%
12%
Net Profit 403 403
66% 66%
7%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Positive
Reuters
●
3 days ago
Incyte said on Monday the European Commission had approved its once-daily oral therapy for ​a type of chronic skin disease.
Neutral
Business Wire
●
3 days ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa.
Neutral
Business Wire
●
10 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte's investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have...
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Mr. Meury
Employees 2,844
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today